KALA Kala Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KALA

Price (delayed)

$7.007

Market cap

$19.73M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$17.35

Enterprise value

$5.16M

Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery ...

Highlights
KALA's quick ratio has soared by 123% YoY and by 12% from the previous quarter
The EPS rose by 41% year-on-year and by 24% since the previous quarter
The revenue has shrunk by 100% YoY
The gross profit has dropped by 100% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://kalarx.com
Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of KALA
Market
Shares outstanding
2.82M
Market cap
$19.73M
Enterprise value
$5.16M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.51
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$36.39M
EBITDA
-$35.91M
Free cash flow
-$28.49M
Per share
EPS
-$17.35
Free cash flow per share
-$11.71
Book value per share
$2.79
Revenue per share
$0
TBVPS
$23.01
Balance sheet
Total assets
$55.95M
Total liabilities
$48.45M
Debt
$36.32M
Equity
$7.5M
Working capital
$44.52M
Liquidity
Debt to equity
4.84
Current ratio
6.33
Quick ratio
6.1
Net debt/EBITDA
0.41
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-66%
Return on equity
-282.8%
Return on invested capital
-106.7%
Return on capital employed
-76.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KALA stock price

How has the Kala Pharmaceuticals stock price performed over time
Intraday
2.74%
1 week
8.47%
1 month
-10.51%
1 year
-54.76%
YTD
0.1%
QTD
-12.08%

Financial performance

How have Kala Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$38.92M
Net income
-$42.2M
Gross margin
N/A
Net margin
N/A
The revenue has shrunk by 100% YoY
The gross profit has dropped by 100% year-on-year
KALA's operating income has soared by 53% YoY
Kala Pharmaceuticals's net income has increased by 9% QoQ and by 6% YoY

Growth

What is Kala Pharmaceuticals's growth rate over time

Valuation

What is Kala Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.51
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 41% year-on-year and by 24% since the previous quarter
Kala Pharmaceuticals's equity has shrunk by 60% YoY and by 33% QoQ
The price to book (P/B) is 33% higher than the last 4 quarters average of 1.9 but 21% lower than the 5-year quarterly average of 3.2
The revenue has shrunk by 100% YoY

Efficiency

How efficient is Kala Pharmaceuticals business performance
The ROIC has shrunk by 79% YoY but it rose by 10% QoQ
The company's return on assets fell by 36% YoY
The return on equity has declined by 8% since the previous quarter

Dividends

What is KALA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KALA.

Financial health

How did Kala Pharmaceuticals financials performed over time
The total assets is 15% more than the total liabilities
KALA's quick ratio has soared by 123% YoY and by 12% from the previous quarter
KALA's current ratio has soared by 89% YoY and by 13% QoQ
The debt to equity has soared by 114% YoY and by 50% from the previous quarter
Kala Pharmaceuticals's equity has shrunk by 60% YoY and by 33% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.